Holen Sie sich die Stockscreener-App
1.22
2.52%
0.03
Schlusskurs vom Vortag:
$1.19
Offen:
$1.2
24-Stunden-Volumen:
2.76M
Relative Volume:
1.00
Marktkapitalisierung:
$100.37M
Einnahmen:
$65,300
Nettoeinkommen (Verlust:
$-84.93M
KGV:
-0.7143
EPS:
-1.708
Netto-Cashflow:
$-83.57M
1W Leistung:
+12.96%
1M Leistung:
+0.83%
6M Leistung:
-27.81%
1J Leistung:
-42.99%
1-Tages-Spanne:
$1.18
$1.27
1-Wochen-Bereich:
$1.075
$1.27
52-Wochen-Spanne:
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Firmenname
Inovio Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 410-3134
Adresse
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.22 | 90.50M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-01-25 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-11-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Fortgesetzt | Jefferies | Hold |
| 2021-09-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Eingeleitet | Jefferies | Hold |
| 2021-03-23 | Eingeleitet | BofA Securities | Neutral |
| 2021-02-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-17 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Hochstufung | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-07-01 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-21 | Eingeleitet | The Benchmark Company | Buy |
| 2020-04-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
| 2017-10-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-06 | Eingeleitet | Citigroup | Buy |
| 2017-06-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Bestätigt | Maxim Group | Buy |
| 2017-03-16 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
Alle ansehen
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Inovio Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch
Inovio Pharmaceuticals, Inc.(NasdaqCM: INO) added to Russell 3000E Growth Benchmark - marketscreener.com
Inovio Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:INO) - TradingView
Price to earnings forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO - TradingView
Price to sales forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO - TradingView
Enterprise value to revenue forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO - TradingView
Inovio Pharmaceuticals, Inc. Actuals & Estimates (BX:GBM) - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
INO stock edges up after hours as partner reports success in cervical dysplasia trial - MSN
Inovio Pharmaceuticals, Inc. Actuals & Estimates (DUS:GBM) - TradingView
Inovio Pharmaceuticals, Inc. Actuals & Estimates (BMV:INO) - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
INO Forecast — Price Target — Prediction for 2027 - TradingView
Inovio Pharmaceuticals Inc (INO) Institutional Confidence - TradingKey
Is Inovio Pharmaceuticals (INO) a High-Stakes Bet Ahead of its October PDUFA Date - Kavout | AI
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Inovio Pharmaceuticals Inc (INO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Inovio Pharmaceuticals Inc (INO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inovio Pharmaceuticals Inc (INO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inovio Pharmaceuticals Inc (INO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inovio Pharmaceuticals Inc (INO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inovio Pharmaceuticals Inc (INO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Inovio Pharmaceuticals Inc (INO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inovio Pharmaceuticals Inc (INO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Inovio Pharmaceuticals Faces Stock Dilution and Legal Battles - timothysykes.com
Inovio Pharmaceuticals(INO) Stock Options Chain | Quotes & News - Moomoo
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - Barchart.com
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm - PR Newswire
Inovio gains on late-stage trial win for DNA shot - MSN
INO Stock Price, Quote & Chart | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill
Inovio Pharma Is Maintained at Neutral by HC Wainwright & Co. - Moomoo
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision - Bez Kabli
INO Maintained by HC Wainwright & Co. -- Price Target Lowered to $2.50 - GuruFocus
H.C. Wainwright lowers Inovio stock price target on share count - Investing.com UK
Finanzdaten der Inovio Pharmaceuticals Inc-Aktie (INO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):